KSE - Delayed Quote KRW

GC Biopharma Corp. (006280.KS)

116,000.00

-1,200.00

(-1.02%)

At close: 3:30:14 PM GMT+9

GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine

GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA).

PR Newswire 2 days ago

006280.KQ

006280.KS
-1.02%
/C O R R E C T I O N -- GC Biopharma/

GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its LSD (lysosomal storage disorder) pipelines at the WORLD Symposium 2025, held from Feb. 3rd to 7th, 2025, in San Diego, USA.

PR Newswire last month

006280.KQ

006280.KS
-1.02%
GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment

GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new drug for Sanfillippo syndrome type A (MPS IIIA).

PR Newswire 4 months ago

006280.KQ

006280.KS
-1.02%
GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group

GC Cell, a fully integrated cell and gene therapy pioneer, is proud to announce the establishment of an MOU for strategic partnership with Bifarma, a frontrunner in stem cell therapy within Indonesia with comprehensive capabilities in R&D, GMP-compliant manufacturing, and the commercialization of cell therapies. Bifarma is a Subsidiary of Southeast Asia's Leading Pharmaceutical, PT Kalbe Farma Tbk.

PR Newswire 9 months ago

006280.KQ

006280.KS
-1.02%
144510.KQ
FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A

GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA (Sanfilippo syndrome Type A) treatment, GC1130A.

PR Newswire 9 months ago

006280.KS
-1.02%
GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings

GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals (KASBP) on June 7-8th at Waltham, Massachusetts as a sponsor to share keynote presentation, present Korean Scientist Awards and conduct global recruitment.

PR Newswire 10 months ago

006280.KS
-1.02%
GC Cell participates 2024 BIO International Convention, Unveiling its future Blueprint 2.0, as the First Korean Business Forum Sponsor

GC Cell, a leader in the cell and gene therapy (CGT) sector within the biopharmaceutical industry, proudly announces its role as the first Korean Business Forum sponsor at the upcoming 2024 BIO International Convention. Set to take place in San Diego from June 3-6, this year's convention is themed "Making the Impossible Possible" and anticipates participation from over 1,500 companies and 20,000 attendees worldwide.

PR Newswire 10 months ago

006280.KS
-1.02%
144510.KQ

144510.KS
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance

GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type A) treatment, GC1130A.

PR Newswire 10 months ago

006280.KS
-1.02%
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval

GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval.

PR Newswire 10 months ago

006280.KS
-1.02%

Performance Overview

Return	006280.KS	KOSPI Composite Index (^KS11)
YTD	-35.38%	+1.38%
1-Year	+5.05%	-10.13%
3-Year	-36.18%	-9.67%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

GC Biopharma Corp. (006280.KS)

GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine

/C O R R E C T I O N -- GC Biopharma/

GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment

GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group

FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A

GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings

GC Cell participates 2024 BIO International Convention, Unveiling its future Blueprint 2.0, as the First Korean Business Forum Sponsor

GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance

GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval

Performance Overview